Most of us think of vaccines in a straightforward way: one shot, one infection prevented. But in the last several years, researchers have been taking a closer look at something more intriguing—whether some routine vaccinations may also be linked to broader health benefits that weren’t the original goal of the vaccine.
These are sometimes called “secondary benefits” or “non-specific effects.” They’re not a reason to treat vaccines like a magic shield against every illness, and they don’t replace the fundamentals (sleep, exercise, blood pressure control, not smoking, etc.). But they may help explain why vaccination programs often improve overall health outcomes in ways that exceed what we’d expect from preventing one single disease.
One of the most talked-about examples right now is the shingles vaccine and its potential relationship to dementia risk.
The shingles shot and dementia: what does “20% lower risk” actually mean?
A major recent study used a powerful “natural experiment” design in Wales, where eligibility for the shingles vaccine was determined by a strict date-of-birth cutoff. That kind of setup helps reduce some of the typical biases that can affect observational research (like healthier people being more likely to seek vaccines). In this analysis, receiving the shingles vaccine was associated with about a 20% relative reduction in new dementia diagnoses over roughly seven years of follow-up.
That “20%” figure is relative, not absolute. In the study, the estimated absolute reduction was a few percentage points across the follow-up period—still meaningful at a population level, but not a guarantee for any one individual.
Other research lines up with the theme. Systematic reviews and meta-analyses have also found that herpes zoster (shingles) vaccination is associated with a lower risk of dementia, including Alzheimer’s disease in some analyses—though researchers consistently emphasize that more work is needed to confirm causality and clarify who benefits most.
Why would a shingles vaccine affect the brain at all?
Scientists are still debating the “why,” but a few leading ideas show up repeatedly:
1) Preventing viral reactivation and downstream inflammation
Shingles comes from reactivation of the varicella-zoster virus, which can inflame nerves and, in some cases, cause complications beyond the skin rash. One theory is that reducing viral reactivation reduces repeated inflammatory hits that may contribute to cognitive decline over time.
2) Protecting blood vessels and overall resilience
Some studies suggest shingles vaccination may be linked with reduced rates of vascular problems (like certain cardiovascular events). Since brain health is strongly tied to vascular health, any reduction in vascular injury and inflammation could indirectly support cognition.
3) “Immune training” effects
Vaccines don’t just teach the adaptive immune system (antibodies and T-cells). There’s growing interest in the concept of trained immunity—the idea that parts of the innate immune system can become better primed after certain exposures, potentially influencing responses to future threats. This is still an evolving area, but it’s one plausible mechanism behind broader protective patterns seen in some vaccine studies.
Flu shots and Alzheimer’s: another consistent association
The shingles vaccine isn’t the only one studied. Multiple papers have reported that influenza vaccination is associated with a lower risk of Alzheimer’s disease or dementia in older adults. For example, a U.S. cohort study found an association between flu vaccination and reduced Alzheimer’s risk in adults 65+.
A separate large cohort analysis (UK Biobank) also reported that influenza vaccination was associated with reduced incident dementia.
Important caveat: association doesn’t equal causation. People who get annual flu shots may differ in many ways (access to care, health behaviors, underlying conditions) from people who don’t. Good studies try to adjust for those differences, but no adjustment is perfect.
Still, when a signal shows up repeatedly across different populations and methods, it’s worth taking seriously—and worth studying with even stronger designs.
Pneumococcal and other routine adult vaccines: a broader pattern?
When researchers zoom out and look across vaccines, some meta-analyses suggest a broader pattern: certain adult vaccinations (including shingles, flu, and pneumococcal vaccines) are associated with lower dementia risk.
The best-supported signal at the moment appears to be the shingles vaccine/dementia link—particularly because of the strong quasi-experimental approach used in Wales.
What this does (and doesn’t) mean for you
What it means:
- Vaccines may offer benefits that go beyond avoiding the “headline” illness—possibly by reducing inflammation, preventing complications, and supporting overall resilience as we age.
- The shingles vaccine in particular has some of the strongest emerging evidence for a relationship with lower dementia incidence, though researchers still want more confirmatory studies.
What it doesn’t mean:
- Vaccines are not proven “dementia prevention shots,” and no study can promise a specific percentage reduction for an individual.
- These findings shouldn’t replace established brain-health strategies—like managing blood pressure, staying physically active, treating hearing loss, controlling diabetes, and maintaining social and cognitive engagement.
The bottom line
The most exciting part of this research isn’t a single number like “20%.” It’s the bigger idea that preventing infections and shaping immune function may influence long-term brain health. As research continues, we may learn which vaccines have the strongest effects, who benefits most, and what mechanisms are responsible.
In the meantime, keeping up with recommended vaccines remains one of the simplest, most practical ways to protect health—especially in older adulthood—while science continues to explore the surprising extra benefits that might come along for the ride.
